CollPlant Appoints Ira Leiderman and Nira Dror to its Board of Directors

REHOVOT, Israel, March 10, 2015 /PRNewswire/ -- CollPlant Ltd. (TASE: CLPT) (OTC: CQPTY), a medical device company leveraging its groundbreaking, plant-based technology to develop a broad spectrum of biomaterials incorporating proprietary recombinant human collagen (rhCollagen) for use in orthopedics, wound healing and general surgery, announced the recent appointments of Ira Leiderman and Nira Dror to its Board of Directors, bringing the Board to eight members.

Commenting on today's news, Yehiel Tal, Chief Executive Officer of CollPlant, noted, "We are pleased to welcome Ira and Nira to CollPlant's Board. Ira's expertise and relationships within the life sciences arena and U.S. capital markets will be invaluable as we pursue our stated goal of listing in the United States, and as we progress toward commercialization of our first products. Additionally, Nira brings to CollPlant deep operational and corporate governance experience."

Mr. Leiderman currently serves as Managing Partner of New York-based Long Trail Advisors LLC. Prior to that, Mr. Leiderman was co-head of the Healthcare Group at Ladenburg Thalmann & Co. from 2008 to 2009, having joined Ladenburg when that firm acquired Punk Ziegel & Company in May 2008. At Punk Ziegel, Mr. Leiderman was Head of Healthcare and a member of the firm's management committee. Earlier in his career, Mr. Leiderman served as a Managing Director at the Palladin Group, an investment management firm, where he oversaw investment transactions in public and private life sciences companies. Prior to that, Mr. Leiderman was a Senior Vice President at Gerard Klauer Mattison (now part of BMO), where he lead the firm's healthcare practice. Mr. Leiderman currently serves on the Board of MarginSurgical, Inc. and is past, Chairman of the Board of Apthera, Inc. Mr. Leiderman holds a B.A. in Biology from the City University of New York, where he also completed his graduate studies in Biology/Immunology.

Ms. Dror is currently Chairperson of the Board of BHI Global Investments Advisory (Israel). She is also a member of the Board of Directors and Audit committee for the following companies: ClickSoftware, Shlomo Insurance Company, S. Shlomo Holding Ltd. and Sharonim Ltd. Ms. Dror holds a B.A. in Economics and Business Administration and an M.B.A. from Tel Aviv University.  

About CollPlant
CollPlant is a medical device firm established in 2004 to focus on advancing regenerative medicine through cutting-edge technology designed to generate and process proprietary recombinant human collagen (rhCollagen), among other patent-protected recombinant proteins. CollPlant is developing a broad spectrum of biomaterials for a wide variety of medical markets, including orthopedics, wound healing, and general surgery. These include: Vergenix™ STR (soft tissue repair matrix), indicated for the treatment of tendinopathy; Vergenix™ FG wound filler, for treatment of acute and chronic wounds, and; Vergenix™ BVF (bone void filler), indicated for spinal fusion procedures in posterolateral approach. CollPlant's business model consists of its own development and manufacturing of medical devices and their commercialization and distribution, together with leading third parties, alongside alliances with leading companies for joint development, manufacturing and marketing of additional products.

For more information about CollPlant, visit http://www.collplant.com  

SOURCE CollPlant Ltd.

Related Links

http://www.collplant.com